Diabetic Kidney Disease

被引:148
|
作者
Bonner, Ryan [1 ,2 ]
Albajrami, Oltjon [1 ,2 ]
Hudspeth, James [1 ,2 ]
Upadhyay, Ashish [1 ,2 ]
机构
[1] Boston Med Ctr, Dept Med, Sect Nephrol, 800 Harrison Ave,G009, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, 800 Harrison Ave,G009, Boston, MA 02118 USA
来源
PRIMARY CARE | 2020年 / 47卷 / 04期
关键词
Diabetic kidney disease; Diabetic nephropathy; Chronic kidney disease; Albuminuria; RENIN-ANGIOTENSIN SYSTEM; CARDIOVASCULAR OUTCOMES; ACE-INHIBITION; DOUBLE-BLIND; THERAPEUTIC TARGET; GLUCOSE CONTROL; RENAL OUTCOMES; DUAL BLOCKADE; TYPE-2; NEPHROPATHY;
D O I
10.1016/j.pop.2020.08.004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Diabetic kidney disease (DKD) is the most common cause of chronic kidney disease in the United States. Approximately 30% to 40% of individuals with diabetes mellitus develop DKD, and the presence of DKD significantly elevates the risk for morbidity and mortality. Understanding of DKD has grown in recent years. This review describes the pathogenesis of DKD and expands on evidence-based strategies for DKD management, integrating traditional approaches for hyperglycemia, hypertension, and albuminuria management with emerging therapeutic options. Given the public health burden of DKD, it is essential to prioritize prevention, recognition, and management of DKD in the primary care setting.
引用
收藏
页码:645 / 659
页数:15
相关论文
共 50 条
  • [21] Lost in translation: assessing the nomenclature change for diabetic kidney disease in Japan
    Babazono, Tetsuya
    Moriya, Tatsumi
    DIABETOLOGY INTERNATIONAL, 2023, 14 (04) : 319 - 326
  • [22] Update of pathophysiology and management of diabetic kidney disease
    Lin, Yi-Chih
    Chang, Yu-Hsing
    Yang, Shao-Yu
    Wu, Kwan-Dun
    Chu, Tzong-Shinn
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2018, 117 (08) : 662 - 675
  • [23] Novel effective drugs for diabetic kidney disease? or not?
    Gentile, Giorgio
    Mastroluca, Daniela
    Ruggenenti, Piero
    Remuzzi, Giuseppe
    EXPERT OPINION ON EMERGING DRUGS, 2014, 19 (04) : 571 - 601
  • [24] Dual Renin-Angiotensin-Aldosterone System Blockade for Diabetic Kidney Disease
    Pichler, Raimund H.
    de Boer, Ian H.
    CURRENT DIABETES REPORTS, 2010, 10 (04) : 297 - 305
  • [25] Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes
    de Bhailis, Aine M.
    Azmi, Shazli
    Kalra, Philip A.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2021, 12
  • [26] Microparticles in diabetic kidney disease
    Kanakalakshmi, Sushma Thimmaiah
    Swaminathan, Shilna Muttickal
    Mohan, Pooja Basthi
    Nagaraju, Shankar Prasad
    Bhojaraja, Mohan, V
    Laxminarayana, Sindhura Lakshmi Koulmane
    CLINICA CHIMICA ACTA, 2022, 531 : 418 - 425
  • [27] Diabetic Kidney Disease and Hypertension
    Stanton, R. C.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2016, 124 (02) : 93 - 98
  • [28] Nonproteinuric diabetic kidney disease
    Yamanouchi, Masayuki
    Furuichi, Kengo
    Hoshino, Junichi
    Ubara, Yoshifumi
    Wada, Takashi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (07) : 573 - 581
  • [29] Diabetic Kidney Disease and the Cardiorenal Syndrome Old Disease, New Perspectives
    Jindal, Ankur
    Garcia-Touza, Mariana
    Jindal, Nidhi
    Whaley-Connell, Adam
    Sowers, James R.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2013, 42 (04) : 789 - +
  • [30] Recent advances in the pharmacotherapeutic management of diabetic kidney disease
    Block, Tomasz J.
    Batu, Duygu
    Cooper, Mark E.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (07) : 791 - 803